CSIMarket



Worst Performing Stocks In Healthcare Sector Over The Past 12 Months



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares declined by -8.45% on average, in Healthcare Sector over the past 12 months.

Here are the Worst performing stocks in Healthcare Sector.




UTRS

$0.001

$-6.1990 -99.98%
Last 12 Months


UTRS

$0.001

$-6.1990 -99.98%



Minerva Surgical Inc

Minerva Surgical Inc stock declined -99.98% over the past 12 months.


Minerva Surgical Inc*s business model focuses on the development and sale of innovative medical devices specifically designed for gynecological procedures.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.009 mill. $ 49.957 mill. $ -33.450 mill. 9 mill. - Y/Y -10.88 %
Market Cap. Revenues TTM Net Income TTM

$ 0.009 mill.


$ 49.957 mill.


$ -33.450 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -10.88 %


MRQ Y/Y - %



MOTS

$0.0375

$-10.5495 -99.65%
Last 12 Months


MOTS

$0.0375

$-10.5495 -99.65%



Motus Gi Holdings Inc

Motus Gi Holdings Inc stock dropped -99.65% over the past 12 months.


Motus Gi Holdings Inc operates as a medical technology company that designs, develops, and commercializes innovative solutions for gastrointestinal endoscopy procedures. Their business model is centered around providing healthcare professionals with advanced imaging and therapeutic technologies to improve patient outcomes and enhance procedural efficiency.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.323 mill. $ -441.767 mill. $ -1.891 mill. 9 mill. - Y/Y -41.28 %
Market Cap. Revenues TTM Net Income TTM

$ 0.323 mill.


$ -441.767 mill.


$ -1.891 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -41.28 %


MRQ Y/Y - %



INBS

$1.89

$-411.3900 -99.54%
Last 12 Months


INBS

$1.89

$-411.3900 -99.54%



Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc shares declined -99.54% over the past 12 months.


Intelligent Bio Solutions Inc*s business model focuses on providing intelligent solutions in the bio industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.931 mill. $ 2.516 mill. $ -10.067 mill. 2 mill. - Y/Y 80.24 %
Market Cap. Revenues TTM Net Income TTM

$ 3.931 mill.


$ 2.516 mill.


$ -10.067 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 80.24 %


MRQ Y/Y - %



SBFM

$0.3908

$-52.6992 -99.26%
Last 12 Months


SBFM

$0.3908

$-52.6992 -99.26%



Sunshine Biopharma Inc

Sunshine Biopharma Inc stock dropped -99.26% over the past 12 months.


Sunshine Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing drugs for the treatment of cancer and other diseases. They utilize their expertise in drug discovery and development to create innovative treatments that target specific molecular targets in order to deliver more effective and personalized therapies for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.003 mill. $ 26.740 mill. $ -4.087 mill. 0 mill. - Y/Y 54.09 %
Market Cap. Revenues TTM Net Income TTM

$ 0.003 mill.


$ 26.740 mill.


$ -4.087 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 54.09 %


MRQ Y/Y - %



BTTX

$0.0073

$-0.9177 -99.21%
Last 12 Months


BTTX

$0.0073

$-0.9177 -99.21%



Better Therapeutics Inc

Better Therapeutics Inc stock went down -99.21% over the past 12 months.


Better Therapeutics Inc is a digital therapeutics company that combines evidenced-based clinical interventions with software technology to address chronic diseases. Their business model revolves around developing and delivering prescription software applications to patients, which are meant to be used alongside pharmaceutical therapies. Their aim is to provide personalized and scalable solutions that have the potential to improve health outcomes and reduce healthcare costs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.281 mill. $ - mill. $ -31.573 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.281 mill.


$ - mill.


$ -31.573 mill.

Employees Shares Outstanding P/E

-


39 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PBLA

$0.38

$-45.0200 -99.16%
Last 12 Months


PBLA

$0.38

$-45.0200 -99.16%



Panbela Therapeutics Inc

Panbela Therapeutics Inc stock dropped -99.16% over the past 12 months.


Panbela Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative and effective treatments for pancreatic cancer. They aim to leverage their expertise in drug development and strategic partnerships to bring novel therapies to the market and address the unmet medical needs of patients with this devastating disease.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.188 mill. $ - mill. $ -27.270 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.188 mill.


$ - mill.


$ -27.270 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



APVO

$0.569

$-66.3110 -99.15%
Last 12 Months


APVO

$0.569

$-66.3110 -99.15%



Aptevo Therapeutics Inc

Aptevo Therapeutics Inc stock dropped -99.15% over the past 12 months.


Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.163 mill. $ - mill. $ -16.151 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.163 mill.


$ - mill.


$ -16.151 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNAZ

$1.01

$-104.5900 -99.04%
Last 12 Months


RNAZ

$1.01

$-104.5900 -99.04%



Transcode Therapeutics Inc

Transcode Therapeutics Inc stock dropped -99.04% over the past 12 months.


Transcode Therapeutics Inc*s business model revolves around developing innovative RNA-based therapies to treat a wide range of diseases. By leveraging their expertise in mRNA biology and proprietary drug delivery technology, they aim to create transformative treatments with optimized safety and efficacy profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.194 mill. $ - mill. $ -17.056 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5.194 mill.


$ - mill.


$ -17.056 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



EVFM

$0.0108

$-1.0592 -98.99%
Last 12 Months


EVFM

$0.0108

$-1.0592 -98.99%



Evofem Biosciences Inc

Evofem Biosciences Inc stock went down -98.99% over the past 12 months.


Evofem Biosciences Inc*s business model focuses on the development and commercialization of innovative products in the women*s sexual and reproductive health sector.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.337 mill. $ 16.012 mill. $ 47.493 mill. 31 mill. - Y/Y -37.98 %
Market Cap. Revenues TTM Net Income TTM

$ 0.337 mill.


$ 16.012 mill.


$ 47.493 mill.

Employees Shares Outstanding P/E

-


31 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -37.98 %


MRQ Y/Y - %



AVTX

$11.8

$-965.0000 -98.79%
Last 12 Months


AVTX

$11.8

$-965.0000 -98.79%



Avalo Therapeutics Inc

Avalo Therapeutics Inc stock went down -98.79% over the past 12 months.


Avalo Therapeutics Inc is a biotechnology company that focuses on developing novel cancer therapies. Their business model revolves around discovering and advancing targeted therapeutics using their proprietary platform technology. They aim to bring innovative treatments to patients by employing a combination of scientific expertise, strategic collaborations, and clinical development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10.151 mill. $ - mill. $ -142.879 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 10.151 mill.


$ - mill.


$ -142.879 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PXMD

$0.2201

$-14.9099 -98.55%
Last 12 Months


PXMD

$0.2201

$-14.9099 -98.55%



Paxmedica Inc

Paxmedica Inc stock declined -98.55% over the past 12 months.


Paxmedica Inc*s business model revolves around providing innovative solutions and technologies in the healthcare sector.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.633 mill. $ - mill. $ -18.149 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.633 mill.


$ - mill.


$ -18.149 mill.

Employees Shares Outstanding P/E

-


7 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ACON

$0.295

$-16.3450 -98.23%
Last 12 Months


ACON

$0.295

$-16.3450 -98.23%



Aclarion Inc

Aclarion Inc shares went down -98.23% over the past 12 months.


Aclarion Inc is a technology company that operates on a software-as-a-service (SaaS) business model. They provide their customers with cloud-based solutions, enabling them to streamline and automate their business processes efficiently. Aclarion offers a range of customizable software solutions, including data management, project management, and collaboration tools, tailored to meet the specific needs of their clients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.606 mill. $ 0.060 mill. $ -6.127 mill. 5 mill. - Y/Y -60.29 %
Market Cap. Revenues TTM Net Income TTM

$ 1.606 mill.


$ 0.060 mill.


$ -6.127 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -60.29 %


MRQ Y/Y - %



STAB

$0.0006

$-0.0314 -98.13%
Last 12 Months


STAB

$0.0006

$-0.0314 -98.13%



Statera Biopharma Inc fka Cytocom Inc

Statera Biopharma Inc Fka Cytocom Inc stock declined -98.13% over the past 12 months.


Statera Biopharma Inc, formerly known as Cytocom Inc, operates as a biotechnology company focused on the development and commercialization of novel immunotherapies for the treatment of cancer and autoimmune diseases. Their business model revolves around advancing their pipeline of therapeutic candidates through preclinical and clinical trials, with the aim to bring innovative treatments to market that can improve patient outcomes and address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.030 mill. $ 3.688 mill. $ -102.535 mill. 50 mill. - Y/Y 183.48 %
Market Cap. Revenues TTM Net Income TTM

$ 0.030 mill.


$ 3.688 mill.


$ -102.535 mill.

Employees Shares Outstanding P/E

-


50 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 183.48 %


MRQ Y/Y - %



SINT

$5.76

$-296.2400 -98.09%
Last 12 Months


SINT

$5.76

$-296.2400 -98.09%



Sintx Technologies Inc

Sintx Technologies Inc stock dropped -98.09% over the past 12 months.


Sintx Technologies Inc is a company that operates under a business model focused on developing and commercializing silicon nitride-based ceramics for various applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 198.495 mill. $ 2.775 mill. $ -8.852 mill. 34 mill. - Y/Y 27.46 %
Market Cap. Revenues TTM Net Income TTM

$ 198.495 mill.


$ 2.775 mill.


$ -8.852 mill.

Employees Shares Outstanding P/E

-


34 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 27.46 %


MRQ Y/Y - %



CNSP

$2.42

$-113.0800 -97.90%
Last 12 Months


CNSP

$2.42

$-113.0800 -97.90%



Cns Pharmaceuticals Inc

Cns Pharmaceuticals Inc stock dropped -97.90% over the past 12 months.


CNS Pharmaceuticals Inc*s business model focuses on developing innovative solutions and treatments for central nervous system diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.085 mill. $ 0.034 mill. $ -17.464 mill. 9 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 21.085 mill.


$ 0.034 mill.


$ -17.464 mill.

Employees Shares Outstanding P/E

-


9 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CMAX

$2.85

$-108.4500 -97.44%
Last 12 Months


CMAX

$2.85

$-108.4500 -97.44%



Caremax Inc

Caremax Inc shares declined -97.44% over the past 12 months.


Caremax Inc operates as a healthcare company providing various services and products. Their business model revolves around offering a wide range of medical and healthcare solutions, including home healthcare, medical equipment, and pharmacy services. They aim to meet the diverse needs of patients, ensuring accessible and quality healthcare options through their integrated model.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 10.648 mill. $ 763.529 mill. $ -207.146 mill. 4 mill. - Y/Y 28.02 %
Market Cap. Revenues TTM Net Income TTM

$ 10.648 mill.


$ 763.529 mill.


$ -207.146 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 28.02 %


MRQ Y/Y - %



AMPE

$0.13

$-4.8200 -97.37%
Last 12 Months


AMPE

$0.13

$-4.8200 -97.37%



Ampio Pharmaceuticals inc

Ampio Pharmaceuticals Inc shares went down -97.37% over the past 12 months.


Ampio Pharmaceuticals Inc is a biopharmaceutical company primarily focused on the development of therapies for debilitating diseases. Their business model revolves around identifying unmet medical needs and developing innovative drug candidates to address these needs. They aim to create value through successful clinical development and commercialization of their products, ultimately benefiting patients and generating revenue for the company.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.105 mill. $ - mill. $ -8.632 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.105 mill.


$ - mill.


$ -8.632 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GRTX

$0.0832

$-2.9868 -97.29%
Last 12 Months


GRTX

$0.0832

$-2.9868 -97.29%



Galera Therapeutics Inc

Galera Therapeutics Inc stock dropped -97.29% over the past 12 months.


Galera Therapeutics Inc is a pharmaceutical company that operates under an innovative business model focused on developing transformative therapies to treat cancer. They utilize a combination of in-house research, strategic partnerships, and scientific collaborations to discover, develop, and commercialize novel drug candidates. By leveraging their expertise and a patient-centric approach, Galera Therapeutics aims to revolutionize cancer treatment and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.784 mill. $ - mill. $ -69.683 mill. 45 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.784 mill.


$ - mill.


$ -69.683 mill.

Employees Shares Outstanding P/E

-


45 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CING

$0.57

$-19.0360 -97.09%
Last 12 Months


CING

$0.57

$-19.0360 -97.09%



Cingulate Inc

Cingulate Inc stock dropped -97.09% over the past 12 months.


Cingulate Inc operates as a software development company, specializing in delivering innovative solutions for various industries. With a focus on cutting-edge technologies, they provide customized software products and services to meet the specific needs of their clients. Their business model revolves around developing and implementing software solutions that optimize processes and enhance efficiency within organizations.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.516 mill. $ - mill. $ -23.535 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.516 mill.


$ - mill.


$ -23.535 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CALA

$0.0125

$-0.3375 -96.43%
Last 12 Months


CALA

$0.0125

$-0.3375 -96.43%



Calithera Biosciences Inc

Calithera Biosciences Inc stock went down -96.43% over the past 12 months.


Calithera Biosciences Inc is a biotechnology company that specializes in developing novel small molecule drugs to treat and potentially cure cancer. Their business model focuses on leveraging their expertise in tumor metabolism to discover and develop innovative therapies that target specific enzymes and pathways involved in cancer cell growth and survival.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.071 mill. $ - mill. $ -21.290 mill. 6 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.071 mill.


$ - mill.


$ -21.290 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MYMD

$2.11

$-50.0900 -95.96%
Last 12 Months


MYMD

$2.11

$-50.0900 -95.96%



Mymd Pharmaceuticals Inc

Mymd Pharmaceuticals Inc shares dropped -95.96% over the past 12 months.


Mymd Pharmaceuticals Inc operates as a biotechnology company that develops and commercializes novel therapies. They focus on creating innovative treatments targeting neurological and psychiatric disorders by leveraging their proprietary drug discovery platform.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.518 mill. $ - mill. $ -12.288 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.518 mill.


$ - mill.


$ -12.288 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ATXI

$3.63

$-83.3700 -95.83%
Last 12 Months


ATXI

$3.63

$-83.3700 -95.83%



Avenue Therapeutics Inc

Avenue Therapeutics Inc shares dropped -95.83% over the past 12 months.


Avenue Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of intravenous (IV) opioids for acute pain management. They aim to address the needs of the hospital-based market by providing innovative and effective IV pain medications. Through research, clinical trials, and partnerships with healthcare providers, Avenue Therapeutics Inc strives to improve healthcare outcomes for patients suffering from acute pain conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.027 mill. $ - mill. $ -7.235 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.027 mill.


$ - mill.


$ -7.235 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VAXX

$0.0994

$-2.1106 -95.50%
Last 12 Months


VAXX

$0.0994

$-2.1106 -95.50%



Vaxxinity Inc

Vaxxinity Inc stock declined -95.50% over the past 12 months.


Vaxxinity Inc is a company that operates on a business model that focuses on the development and distribution of vaccines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 12.576 mill. $ - mill. $ -56.934 mill. 127 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 12.576 mill.


$ - mill.


$ -56.934 mill.

Employees Shares Outstanding P/E

-


127 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HSCS

$5.11

$-94.0800 -94.85%
Last 12 Months


HSCS

$5.11

$-94.0800 -94.85%



Heart Test Laboratories Inc

Heart Test Laboratories Inc shares dropped -94.85% over the past 12 months.


Heart Test Laboratories Inc operates as a medical diagnostic company that specializes in heart testing. Their business model revolves around providing innovative and accurate cardiovascular diagnostic tests to healthcare facilities and patients, aimed at early detection and prevention of heart diseases. They achieve this by leveraging advanced technology, collaborating with medical professionals, and offering their services through partnerships with hospitals, clinics, and physicians.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.559 mill. $ 0.006 mill. $ -6.090 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.559 mill.


$ 0.006 mill.


$ -6.090 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AFIB

$0.0471

$-0.8129 -94.52%
Last 12 Months


AFIB

$0.0471

$-0.8129 -94.52%



Acutus Medical Inc

Acutus Medical Inc stock went down -94.52% over the past 12 months.


Acutus Medical Inc is a medical technology company that develops and commercializes products for the diagnosis and treatment of cardiac arrhythmias. Their business model focuses on producing innovative and advanced medical devices, such as 3D imaging and mapping systems, to help physicians accurately identify and treat irregular heart rhythms.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.399 mill. $ 47.447 mill. $ -66.968 mill. 30 mill. - Y/Y -28.78 %
Market Cap. Revenues TTM Net Income TTM

$ 1.399 mill.


$ 47.447 mill.


$ -66.968 mill.

Employees Shares Outstanding P/E

-


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -28.78 %


MRQ Y/Y - %



DMTK

$0.1455

$-2.4645 -94.43%
Last 12 Months


DMTK

$0.1455

$-2.4645 -94.43%



Dermtech Inc

Dermtech Inc stock dropped -94.43% over the past 12 months.


Dermtech Inc is a biotechnology company that specializes in non-invasive diagnostic tests for skin cancer and other skin conditions. Their business model revolves around developing and commercializing their proprietary technology, which allows for the accurate and early detection of skin cancer through a simple adhesive patch. By providing dermatologists with a less invasive and more efficient diagnostic tool, Dermtech aims to improve patient outcomes and revolutionize the field of dermatology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5.050 mill. $ 13.370 mill. $ -101.807 mill. 35 mill. - Y/Y 24.01 %
Market Cap. Revenues TTM Net Income TTM

$ 5.050 mill.


$ 13.370 mill.


$ -101.807 mill.

Employees Shares Outstanding P/E

-


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 24.01 %


MRQ Y/Y - %



VRPX

$0.5701

$-9.3299 -94.24%
Last 12 Months


VRPX

$0.5701

$-9.3299 -94.24%



Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc shares declined -94.24% over the past 12 months.


Virpax Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative non-opioid products to address the unmet needs in pain management. Their business model revolves around research, development, and commercialization of these non-opioid solutions to provide effective and safe pain relief options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.668 mill. $ - mill. $ -13.615 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.668 mill.


$ - mill.


$ -13.615 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LGVN

$2.22

$-35.0800 -94.05%
Last 12 Months


LGVN

$2.22

$-35.0800 -94.05%



Longeveron Inc

Longeveron Inc shares went down -94.05% over the past 12 months.


Longeveron Inc*s business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.702 mill. $ 0.800 mill. $ -20.231 mill. 2 mill. - Y/Y -43.40 %
Market Cap. Revenues TTM Net Income TTM

$ 4.702 mill.


$ 0.800 mill.


$ -20.231 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -43.40 %


MRQ Y/Y - %



EFTR

$1.16

$-18.2150 -94.01%
Last 12 Months


EFTR

$1.16

$-18.2150 -94.01%



Effector Therapeutics Inc

Effector Therapeutics Inc shares declined -94.01% over the past 12 months.


Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.866 mill. $ - mill. $ -35.941 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2.866 mill.


$ - mill.


$ -35.941 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ADTX

$1.44

$-22.1600 -93.90%
Last 12 Months


ADTX

$1.44

$-22.1600 -93.90%



Aditxt Inc

Aditxt Inc stock declined -93.90% over the past 12 months.


Aditxt Inc operates on a business model that focuses on developing and commercializing technologies used in the field of biotechnology and personalized medicine. They leverage their expertise in genomics and diagnostics to offer innovative solutions that enable individuals to better understand and manage their health. Through their products and services, Aditxt aims to deliver personalized diagnostics and immune monitoring platforms to empower people in making informed decisions about their well-being.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.293 mill. $ 0.749 mill. $ -29.520 mill. 0 mill. - Y/Y -61.47 %
Market Cap. Revenues TTM Net Income TTM

$ 0.293 mill.


$ 0.749 mill.


$ -29.520 mill.

Employees Shares Outstanding P/E

-


0 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -61.47 %


MRQ Y/Y - %



BTAI

$1.22

$-18.6500 -93.86%
Last 12 Months


BTAI

$1.22

$-18.6500 -93.86%



Bioxcel Therapeutics Inc

Bioxcel Therapeutics Inc stock went down -93.86% over the past 12 months.


BioXcel Therapeutics Inc. is a biopharmaceutical company that operates using an innovative business model. They utilize artificial intelligence (AI) and big data analytics to identify and develop novel therapies for targeted diseases with unmet medical needs. This approach allows them to leverage data-driven insights to expedite drug discovery and development, potentially increasing the efficiency and success rate of their drug candidates.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 37.659 mill. $ 1.756 mill. $ -153.048 mill. 31 mill. - Y/Y 182.52 %
Market Cap. Revenues TTM Net Income TTM

$ 37.659 mill.


$ 1.756 mill.


$ -153.048 mill.

Employees Shares Outstanding P/E

51


31 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 182.52 %


MRQ Y/Y - %



FGEN

$1.03

$-15.6500 -93.82%
Last 12 Months


FGEN

$1.03

$-15.6500 -93.82%



Fibrogen Inc

Fibrogen Inc shares went down -93.82% over the past 12 months.


Fibrogen Inc*s business model focuses on the development and commercialization of innovative therapeutics for unmet medical needs. They aim to discover and create treatments by leveraging their expertise in fibrosis and tissue regeneration. Fibrogen Inc collaborates with strategic partners and utilizes its extensive research and development capabilities to bring these therapies to market and improve the lives of patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 101.192 mill. $ 154.980 mill. $ -294.175 mill. 98 mill. - Y/Y 155.06 %
Market Cap. Revenues TTM Net Income TTM

$ 101.192 mill.


$ 154.980 mill.


$ -294.175 mill.

Employees Shares Outstanding P/E

832


98 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 155.06 %


MRQ Y/Y - %



KTRA

$0.216

$-3.2240 -93.72%
Last 12 Months


KTRA

$0.216

$-3.2240 -93.72%



Kintara Therapeutics Inc

Kintara Therapeutics Inc stock went down -93.72% over the past 12 months.


Kintara Therapeutics Inc*s business model revolves around the development and commercialization of innovative therapies for the treatment of various types of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.371 mill. $ - mill. $ -13.023 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.371 mill.


$ - mill.


$ -13.023 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GNLX

$2.37

$-34.4200 -93.56%
Last 12 Months


GNLX

$2.37

$-34.4200 -93.56%



Genelux Corporation

Genelux Corporation shares dropped -93.56% over the past 12 months.


Genelux Corporation*s business model revolves around the development and commercialization of innovative genetic-based therapies and technologies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 57.814 mill. $ - mill. $ -28.297 mill. 24 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 57.814 mill.


$ - mill.


$ -28.297 mill.

Employees Shares Outstanding P/E

-


24 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GNPX

$2.08

$-29.9240 -93.50%
Last 12 Months


GNPX

$2.08

$-29.9240 -93.50%



Genprex Inc

Genprex Inc shares went down -93.50% over the past 12 months.


Genprex Inc*s business model focuses on the development and commercialization of gene therapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.366 mill. $ - mill. $ -27.627 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 3.366 mill.


$ - mill.


$ -27.627 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



AMLX

$1.62

$-22.8100 -93.37%
Last 12 Months


AMLX

$1.62

$-22.8100 -93.37%



Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc shares went down -93.37% over the past 12 months.


Amylyx Pharmaceuticals Inc*s business model revolves around researching, developing, and commercializing potential therapies for neurodegenerative diseases. They aim to identify promising drug candidates, conduct preclinical and clinical trials, and ultimately gain regulatory approval to market and sell their products. By focusing on innovative treatments, Amylyx Pharmaceuticals Inc aims to address unmet medical needs in the field of neurodegenerative disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 112.993 mill. $ 294.222 mill. $ 1.836 mill. 70 mill. - Y/Y 29,666.09 %
Market Cap. Revenues TTM Net Income TTM

$ 112.993 mill.


$ 294.222 mill.


$ 1.836 mill.

Employees Shares Outstanding P/E

80


70 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 29,666.09 %


MRQ Y/Y - %



NMRD

$0.045

$-0.6050 -93.08%
Last 12 Months


NMRD

$0.045

$-0.6050 -93.08%



Nemaura Medical Inc

Nemaura Medical Inc stock declined -93.08% over the past 12 months.


Nemaura Medical Inc*s business model revolves around developing innovative and cost-effective medical technologies and devices.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ - mill. $ -10.651 mill. - mill. 0.12 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ - mill.


$ -10.651 mill.

Employees Shares Outstanding P/E

-


- mill.


0.12

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LYRA

$0.2588

$-3.4312 -92.99%
Last 12 Months


LYRA

$0.2588

$-3.4312 -92.99%



Lyra Therapeutics Inc

Lyra Therapeutics Inc stock declined -92.99% over the past 12 months.


Lyra Therapeutics Inc is a biotechnology company that focuses on developing drug-delivery systems for patients with ear, nose, and throat (ENT) diseases. They utilize their proprietary technology, known as XTreo, to precisely deliver therapeutics to targeted areas within the ENT region. Their business model revolves around developing and commercializing these unique drug-delivery solutions to address unmet medical needs in the ENT field.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 14.740 mill. $ 1.423 mill. $ -61.759 mill. 57 mill. - Y/Y 51.53 %
Market Cap. Revenues TTM Net Income TTM

$ 14.740 mill.


$ 1.423 mill.


$ -61.759 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 51.53 %


MRQ Y/Y - %



BPTH

$2.27

$-29.3300 -92.82%
Last 12 Months


BPTH

$2.27

$-29.3300 -92.82%



Bio path Holdings Inc

Bio Path Holdings Inc shares declined -92.82% over the past 12 months.


Bio path Holdings Inc is a biotechnology company focused on developing RNA-based therapeutics for the treatment of diseases such as cancer. Their business model involves researching, developing, and commercializing these therapies to provide improved treatment options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.469 mill. $ - mill. $ -13.962 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.469 mill.


$ - mill.


$ -13.962 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



REVB

$2.31

$-29.1900 -92.67%
Last 12 Months


REVB

$2.31

$-29.1900 -92.67%



Revelation Biosciences Inc

Revelation Biosciences Inc stock went down -92.67% over the past 12 months.


Revelation Biosciences Inc*s business model focuses on developing innovative therapies and technologies for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.485 mill. $ - mill. $ 0.875 mill. 0 mill. 0.06 Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.485 mill.


$ - mill.


$ 0.875 mill.

Employees Shares Outstanding P/E

-


0 mill.


0.06

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com